Outcomes for patients who received LMP-Ts as adjuvant therapy vs treatment for active disease. Patients who received LMP-Ts as adjuvant therapy after HSCT had superior 2-year EFS (A) and OS (B) compared with patients who had active disease at the time of LMP-T infusion.